Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001764013-23-000133
Filing Date
2023-11-09
Accepted
2023-11-09 07:13:12
Documents
55
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q imvt-20230930.htm   iXBRL 10-Q 1256845
2 EX-31.1 exhibit311-2023930q2.htm EX-31.1 9513
3 EX-31.2 exhibit312-2023930q2.htm EX-31.2 9414
4 EX-32.1 exhibit321-2023930q2.htm EX-32.1 4465
5 EX-32.2 exhibit322-2023930q2.htm EX-32.2 4486
  Complete submission text file 0001764013-23-000133.txt   4619893

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT imvt-20230930.xsd EX-101.SCH 28244
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT imvt-20230930_cal.xml EX-101.CAL 37995
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT imvt-20230930_def.xml EX-101.DEF 171419
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT imvt-20230930_lab.xml EX-101.LAB 405954
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT imvt-20230930_pre.xml EX-101.PRE 275998
49 EXTRACTED XBRL INSTANCE DOCUMENT imvt-20230930_htm.xml XML 381709
Mailing Address 320 WEST 37TH STREET NEW YORK NY 10018
Business Address 320 WEST 37TH STREET NEW YORK NY 10018 917-580-3099
Immunovant, Inc. (Filer) CIK: 0001764013 (see all company filings)

EIN.: 832771572 | State of Incorp.: DE | Fiscal Year End: 0331
Type: 10-Q | Act: 34 | File No.: 001-38906 | Film No.: 231390036
SIC: 2836 Biological Products, (No Diagnostic Substances)